| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Undecanoic acid targets fungal enzymes and biosynthetic pathways. Its mechanism of action involves the inhibition of the production of extracellular keratinase and lipase, as well as the biosynthesis of various phospholipids in T. rubrum. By inhibiting these key enzymes and pathways, it disrupts the fungus's ability to invade and metabolize keratin, ultimately leading to its antifungal effect.
|
|---|---|
| ln Vitro |
In vitro, undecanoic acid exhibits antifungal activity against T. rubrum. It inhibits the production of exocellular keratinase, lipase, and the biosynthesis of several phospholipids. Detailed IC50 values for these activities are not extensively reported in the available literature. Its activity is confirmed through antifungal susceptibility testing.
|
| ln Vivo |
Detailed in vivo activity data for undecanoic acid are not extensively reported in the available literature. As a monocarboxylic acid with antifungal properties, it is expected to have potential for in vivo efficacy in treating fungal infections. Its presence in body fluids suggests it may play a role in the body's natural defense against fungi.
|
| Enzyme Assay |
Non-cell-based assays for undecanoic acid include antifungal susceptibility testing. The minimum inhibitory concentration (MIC) is determined using broth microdilution or agar dilution methods against fungal strains such as T. rubrum. Its mechanism of action can be studied by measuring its effects on keratinase, lipase, and phospholipid biosynthesis in cell-free systems.
|
| Cell Assay |
Cellular assays for undecanoic acid are performed using fungal cultures, such as T. rubrum. Fungi are treated with the compound at various concentrations, and growth inhibition is assessed. The production of extracellular enzymes and phospholipids is measured to confirm the compound's mechanism of action.
|
| Animal Protocol |
In vivo animal models for undecanoic acid would be required to assess its therapeutic potential. Based on its mechanism as an antifungal agent, relevant models could include models of dermatophytosis, such as guinea pig or mouse models of T. rubrum infection. The compound would be administered topically or systemically, and fungal burden and clinical signs would be assessed.
|
| ADME/Pharmacokinetics |
Undecanoic acid has a molecular weight of 186.29 g/mol and a molecular formula of C₁₁H₂₂O₂. Its CAS number is 112-37-8. The compound is a colorless liquid with a characteristic odor. Purity is typically >98%. Storage conditions: room temperature. The compound is supplied for research use only.
|
| Toxicity/Toxicokinetics |
Undecanoic acid is generally considered safe at the concentrations used for research. The compound is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
Undecanoic acid is a white crystalline solid, insoluble in water, with a specific gravity of 0.85, thus floating on water. It is a straight-chain, 11-carbon, saturated medium-chain fatty acid found in body fluids and is the most antifungal active fatty acid in the C7:0-C18:0 fatty acid series. It is both a human metabolite and an antifungal agent. It is both a straight-chain saturated fatty acid and a medium-chain fatty acid. It is the conjugate acid of undecanoic acid, derived from the hydride of undecane. Undecanoic acid has been reported to be detected in Listeria guineensis, Streptomyces, and other organisms with relevant data. Undecanoic acid is a metabolite of, or produced by, Saccharomyces cerevisiae.
Undecanoic acid is also known as undecanoate and hendecanoic acid. It is a monocarboxylic acid with antifungal properties, particularly against T. rubrum. It inhibits the production of extracellular keratinase and lipase and the biosynthesis of phospholipids. Its CAS number is 112-37-8. |
| Molecular Formula |
C11H22O2
|
|---|---|
| Molecular Weight |
186.3
|
| Exact Mass |
186.161
|
| CAS # |
112-37-8
|
| Related CAS # |
Undecanoic acid-d21;60658-40-4;Undecanoic acid-d3;1219802-11-5;Undecanoic acid-d2;64118-43-0
|
| PubChem CID |
8180
|
| Appearance |
Colorless to light yellow <28°C powder,>31°C liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
283.3±3.0 °C at 760 mmHg
|
| Melting Point |
28-31 °C(lit.)
|
| Flash Point |
128.2±11.9 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.446
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
13
|
| Complexity |
121
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
ZDPHROOEEOARMN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H22O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h2-10H2,1H3,(H,12,13)
|
| Chemical Name |
undecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~536.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3677 mL | 26.8384 mL | 53.6769 mL | |
| 5 mM | 1.0735 mL | 5.3677 mL | 10.7354 mL | |
| 10 mM | 0.5368 mL | 2.6838 mL | 5.3677 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
